CER-001 Atherosclerosis Regression ACS Trial

Overview

The purpose of this study is to assess the impact of ten intravenous infusions of 3 mg/kg CER 001 vs. placebo, given at weekly intervals for ten weeks, on atherosclerotic plaque volume as measured by coronary IVUS, when administered to subjects presenting with Acute Coronary Syndrome (ACS) with significant plaque volume.

Full Title of Study: “CER-001 Atherosclerosis Regression ACS Trial; A Phase II Multi-Center, Double-Blind, Placebo-Controlled, Dose-Focusing Trial Of Cer-001 In Subjects With Acute Coronary Syndrome”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: November 2016

Detailed Description

Subjects will be required to have at least one epicardial coronary artery suitable for IVUS imaging. A suitable target artery for IVUS imaging will be determined at baseline as having stenosis of up to 50% and meeting all angiographic inclusion criteria. Subjects having met all eligibility criteria will be randomized to receive an intravenous infusion of CER 001 (3 mg/kg) or placebo within 14 days of event presentation. Randomized subjects will then return at 7 day intervals for nine additional infusions. A follow up IVUS will be conducted at 14 days after the last infusion. The total study duration from randomization to follow up IVUS for a completed study can range from approximately 9 to 12 weeks.

Interventions

  • Drug: CER-001
    • Engineered pre-beta HDL particle
  • Drug: Placebo
    • Normal saline

Arms, Groups and Cohorts

  • Experimental: CER-001
    • CER-001 infusion
  • Placebo Comparator: Placebo
    • Placebo infusion

Clinical Trial Outcome Measures

Primary Measures

  • Nominal Change in Percent Atheroma Volume (PAV)
    • Time Frame: Baseline to 12 weeks
    • The nominal change from baseline to follow-up (at 12 weeks) in the percent atheroma volume (PAV) in the target coronary artery assessed by 3 dimensional (3D) IVUS

Secondary Measures

  • Nominal Change in Normalized Total Atheroma Volume (TAV)
    • Time Frame: Baseline to 12 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female greater than 18 years of age – Acute coronary syndrome (myocardial infarction or unstable agina) – Angiographic evidence of coronary artery disease with suitable "target" coronary artery for IVUS evaluation Exclusion Criteria:

  • Females of child-bearing potential – Angiographic evidence of >50% stenosis of the left main artery – Uncontrolled diabetes (HbA1C>10%) – Hypertriglyceridemia (>500 mg/dL) – Congestive heart failure (NYHA class III or IV) – Ejection fraction <35% – Uncontrolled hypertension (SBP >180 mm Hg) – Known major hematologic, renal, hepatic, metabolic, gastrointestinal or endocrine dysfunction

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Cerenis Therapeutics, SA
  • Collaborator
    • South Australian Health and Medical Research Institute
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Connie Keyserling, MS, Study Director, Cerenis Therapeutics
    • Stephen Nicholls, MD PhD, Study Chair, South Australian Health and Medical Research Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.